Cmet Expression and Activity of First-Line Erlotinib in Advanced Non-Small Cell Lung Cancer (Nsclc) Patients (Pts): Exploratory Analysis of the Randomized Phase III Torch Trial
M. Tsao1, M. Di Maio2, L. Kim1, G. Liu3, J. Xu1, V. Gebbia4, M.A. Burgio5, Z.Y. Alam6, G. Valmadre7, B. Higgins8, S. Signoriello9, A. Rossi10, N.B. Leighl3, P. Maione10, C.A. Butts11, F. Ciardiello12, R. Feld3, C. Gallo9, C. Gridelli10, F. Perrone2
1Pathology Department, Princess Margaret Cancer Centre, Toronto, ON, CANADA
2Clinical Trials Unit, Istituto Nazionale Tumori – I.R.C.C.S - Fondazione Pascale, Naples, ITALY
3Medical Oncology, Princess Margaret Hospital, Toronto, ON, CANADA
4Medical Oncology Unit, La Maddalena Clinic for Cancer, Palermo, Italy
5Medical Oncology, IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.), Meldola, Meldola (FC), ITALY
6Medical Oncology, Windsor Regional Cancer Centre, Windsor, ON, CANADA
7Dept. of Internal Medicine and Hematology, Ospedale E. Morelli AOVVAzienda Ospedaliera Valtellina e Valchiavenna, Sondalo, ITALY
8Medical Oncology, Peel Regional Cancer Centre, Credit Valley Hospital, Mississauga, ON, CANADA
9Medical Statistics, Second University, Naples, ITALY
10Medical Oncology, Azienda Ospedaliera S. Giuseppe Moscati, Avellino, ITALY
11Department of Oncology, University of Alberta, Cross Cancer Institute, Edmonton, AB, Canada
12Dip. Medico Chirurgico Di Internistica, Seconda Università Studi di Napoli Policlinico Federico II, Naples, ITALY